Washington-based Nanochon secure an investment from cultivate(MD) capital funds. Sports medicine doctors use Nanochon’s procedures to treat active individuals who need cartilage restoration.
Read also- NYC-based Hang Secures $9.2M in Series A Round Funding
With the help of an innovative material and 3D printed designs, Nanochon’s ChondrograftTM restores missing or hurt cartilage and promotes new development in a simple and affordable treatment solution.
Benjamin Holmes, PhD, CEO of Nanochon said, “We at Nanochon are thrilled to welcome cultivate(MD) as a key investor and valued member of our Board of Directors. Their investment and board participation represent a significant vote of confidence in our vision and technology. This collaboration is a crucial step towards accelerating our groundbreaking work in revolutionizing joint health and regenerative treatments and will enable us to establish a new standard in minimally invasive, durable, and restorative treatments.”
Given that Nanochon treats localised cartilage abnormalities in the active patient group aged 18 to 55, they are an excellent match for this description. Their innovative implant is currently undergoing final setup for first-in-human trials, having shown unmatched outcomes throughout numerous equine tests.
About Nanochon
Nanochon is creating an implant that will encourage the creation of new tissue in addition to repairing lost or damaged cartilage. The Nanochon implant is a robust medical device that combines tissue growth scaffolding with orthopaedic load bearing using 3-D printing and a unique material.
Read also – San Francisco-based Every.io Secures $9.5M in Seed Funding
The Nanochon implant has the potential to lower costs for patients, payers, and healthcare providers while facilitating quicker and more successful patient recoveries. The goal of Nanochon is to create a new clinical benchmark for cartilage regeneration.
